Biobanking Market By Type (Equipment {Sample Collection Systems, Processing Equipment, Storage Equipment, Sample Transport Systems}, Consumables {Cryovials & Tubes, Reagents & Kits, Cryogenic Labels & Racks, Bags & Containers}, Services {Biobanking & Repository Services, Sample Processing & Analysis Services, Genomic Sequencing Services, Others}), By Application (Regenerative Medicine, Life Science Research, Clinical Research, Drug Discovery & Development, Personalized Medicine, Disease Epidemiology, Others), By Sample Type (Blood Products, Human Tissues, Stem Cells, DNA/RNA Samples, Cells & Cell Lines, Others), By Storage Type (Manual Storage, Automated Storage, Cryogenic Storage, Mechanical Storage), and By End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Biobanking Market in the coming years?

The Biobanking Market accounted for USD 82.64 Billion in 2024 and USD 89.19 Billion in 2025 is expected to reach USD 191.12 Billion by 2035, growing at a CAGR of around 7.92% between 2025 and 2035. The biobanking market is defined as the type of industry that deals with harvesting, storing, and overseeing biological samples (blood, tissues, cells, and DNA) to be used in research and medical practices. Such biobanks are essential resources in creating new diagnostics, personalised medicine, and drug discovery. Organisations that provide biobanking services, equipment, and software to preserve sample integrity and data management are found in the market. The increase in the market of precision medicine and biotechnology is fuelling the growth in this market globally.

What do industry experts say about the Biobanking market trends?

“Biobanking is a cornerstone of precision medicine, as it enables the collection and preservation of high-quality biological samples for translational research and drug development.”

• Dr. Kurt Zatloukal, MD – Professor of Pathology, Medical University of Graz, Austria

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Biobanking market?

How does increasing personalized medicine demand accelerate biobanking growth?

With the growing interest in personalised medicine, the growth of biobanking is being accelerated by the development of an urgent demand for large, well-organised repositories of biological samples associated with detailed clinical information. Personalised medicine only customises therapies based on the genetic and lifestyle characteristics of an individual, which means that research needs a wide variety of high-quality biospecimens.

For instance, the All of Us Research Program of the U.S. NIH seeks to gather data on more than a million participants to help develop precision medicine. Further, the UK Biobank, which has a population of 500,000 volunteers, aids in discovering genetic and environmental causes of disease. These biobanks give the necessary infrastructure for the discovery of biomarkers and the development of specific cures.

Besides, biobanks also facilitate longitudinal research studies, which monitor disease progress and treatment response over time, enhancing healthcare outcomes. With the current expansion of personalised medicine, the use of biobanks is increasing to facilitate individualised medicine, which is fuelling growth and development in the field.

Can expanding genomic research initiatives drive biobanking market expansion?

One of the key factors that has propelled the growth of the biobanking market is the expansion of genomic research initiatives. Large-scale genome sequencing projects and personalised medicine programmes are growing more popular among governments and academic institutions across the world, and come with requirements of huge volumes of biological samples and data stored in biobanks. As an illustration, the UK Biobank, with the help of the UK government, has gathered samples and health information of more than 500,000 individuals to allow complex genome research.

The U.S. National Institutes of Health (NIH) established the All of Us Research Program that seeks to collect genomic and health data of at least one million individuals to speed up precision medicine. These initiatives highlight the significance of biobanks as important repositories of high-quality biospecimens that drive genetic studies. The ever-increasing production of genomic data creates an environment of need for biobanking infrastructure and services, widening the biobanking market. With governments accelerating national genomics efforts, it forms a sustainable basis on which biobanks can be developed and improved in healthcare.

Does stringent regulatory compliance hinder biobank operational scalability?

Strict compliance with regulations can be a serious obstacle to the scaling of the operations of biobanks. The U.S. National Cancer Institute demonstrated that a significant portion of biobanks have challenges as a result of a small staff number as well as financial limitations, which are complicated by the necessity to comply with stringent ethical, legal, and privacy regulations. Such compliance can be very costly in terms of investments in data security, consent management, and quality control procedures, which small biobanks can barely afford, restricting their expandability. Moreover, the variability and multidimensionality of regulations at different locations cause inefficiency in operations and delays in the expansion of expansion or cooperation between countries.

According to a European study published by the European Biobank Network, keeping pace with changing legal frameworks requires many resources, which in most cases puts pressure on the biobanks' budgets and staff. Moreover, the existence of old or disjointed legislation in most countries brings about uncertainties, which require biobanks to spend more time and money on the compliance process, which is at the expense of scaling activities. Regulatory oversight, in general, provides ethical conditions and protection of the participants, but because of its strictness, it limits the scalability of biobanks, raising the cost of their operation and administrative overhead.

Can emerging digitalization trends improve biobank data management systems?

The new trends of digitalisation are changing the way biobanks manage their data through facilitating efficient, secure, and scalable use of large biological data sets. Cloud computing technologies enable the sharing of data in real-time and between institutions through biobanks, which enhance cooperation and help in accelerating research. The National Institutes of Health (NIH) states that the incorporation of digital tools can shorten the time of data retrieval by up to 50% to improve the efficiency of operations. According to the research conducted by such organisations as Harvard Medical School, blockchain is also being researched with regard to data integrity and secure consent management.

The innovations assist biobanks in meeting the privacy laws, like HIPAA, with transparent audit trails. Bioinformatics training is also becoming very popular in universities as a result of the rise of digital skills. The net result of the digitalisation is that it enables more dynamic and interoperable biobank systems, accelerating personalised medicine and biomedical research.

Will collaborations with pharmaceutical companies create novel biobanking ventures?

Partnerships between biobanking initiatives and pharmaceutical companies are fostering the capacity to generate innovations in drug development and customised medicine. As an example, the All of Us Research Program is an initiative sponsored by the U.S. National Institutes of Health (NIH) that gathers a variety of biological samples and health data that can be used to find specific therapies.

This massive biobank with a public-private partnership, according to NIH, improves data sharing and the speed of biomarker discovery in new drugs. Likewise, government initiatives like the UK Biobank, which has collected biological samples of more than 500,000 individuals, are actively engaged in partnership with pharma companies to drive disease-mechanism research and new therapies.

Such collaborations enhance access to strongly characterised samples and related data, resulting in the creation of accurate treatments and enhancing the effectiveness of clinical trials. Therefore, the development of new biobanking initiatives to revolutionise healthcare by using the power of data requires pharmaceutical partnerships.

What are the key market segments in the Biobanking industry?

Based on the type, the Biobanking Market is classified into Equipment, Consumables, and Services. The equipment segment is the most conspicuous and dominant in the biobanking market. This is because biobanks need advanced and specialised machinery, including cryogenic storage facilities, automated sample processing devices, and ultra-low temperature freezers, to ascertain the correct preservation and manipulation of biological samples.

High share in this segment is fuelled by the increasing need to provide high-quality and reliable storage systems that will preserve the integrity of samples. Moreover, the popularity of equipment in the biobanking ecosystem is boosted by the ongoing technological improvement and the rise in the number of investments in the infrastructure.

Based on the application, the Biobanking Market is classified into Regenerative Medicine, Life Science Research, Clinical Research, Drug Discovery & Development, Personalized Medicine, Disease Epidemiology, and Others. The most notable and important application area in the biobanking market is the life science research segment. Biobanks are important in delivering quality biological specimens to support basic and translational research to enable scientists to comprehend the mechanisms of diseases and genetic variation.

The dominance of this segment is due to the extent of use of biobanked specimens in genomics, proteomics, and biomarker discovery. Moreover, the increasing focus on personalised medicine and the demand for the soundness of research data to create new treatment methods further prove life science research as the most successful application in biobanking.

Which regions are leading the Biobanking market, and why?

The North American market of biobanking is dominant because of its well-built healthcare systems and prioritised attention on biomedical research. The region has a significant government investment and favourable regulatory support that promotes innovation and the sharing of data. It is worth noting that the need to obtain high-quality biospecimens is stimulated by the existence of many well-known research institutions and pharmaceutical companies.

Biobanking activities are also enhanced by the rising rates of chronic diseases and the rising use of personalised medicine. Further, the established IT infrastructure of North America also permits the effective management and integration of data, and biobanks are more accessible and useful in research. Also highlighted in the region are ethical standards and consent of the patients, which strengthen the trust and involvement in the biobanking projects. All these combine to support a strong ecosystem that places the North American continent at the centre of the biobanking market.

The Asia-Pacific biobanking market is quickly becoming a major player owing to a number of prominent factors. The area has been blessed with a very big and genetically varied population, and this is very significant in gathering differing biological samples that spearhead the progressive research. The growing interest in developing healthcare infrastructure and government-sponsored policies to promote biomedical research has boosted the pace of biobanking activities.

Increasing recognition of personalised medicine and the increasing rates of chronic disease have created a demand for biobank resources. The market is also enhanced by technological development and partnership between the government and the commercial world. The growing pharmaceutical and biotechnology markets in such countries as China, Japan, and India also play a major role in the biobanking dominance of the region. Overall, the region of Asia Pacific can be considered to be a vivid centre of biobanking due to a set of demographic benefits, favourable policies, and novelty.

What does the competitive landscape of the Biobanking market look like?

Competition in the biobanking market is characterised by well-established players who are increasingly innovative in an effort to respond to the increasing demand for high-quality sample storage and management products and services. The major players, such as Thermo Fisher Scientific, Tecan Group, Avantor, and Qiagen, have been very active in developing their holdings through acquisitions and technology amalgamation, with the aim being automation and digital applications to improve efficiency. Recent activities also focused on the enhancement of cold storage technologies and cloud-based information management to provide improved traceability and security of biospecimens.

Businesses are actively entering into partnerships with research centres to gain access to larger sample sizes and improve personalised medicine programmes. As the world continues with increasing investments in genomic and clinical research, the biobanking market is rapidly developing, and it is technological innovation as well as strategic alliances that have caused it. The sustainability issue is also taking precedence, where companies are looking into energy-saving storage options to lessen environmental harm. In addition to this, there is an increasing trend of biobanking in the emerging markets of Asia and Latin America, which offers new opportunities for expansion to industry players.

Biobanking Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Biobanking industry?

• In June 2025, Cryptobiotix, a biotech company specializing in microbiome modeling with its SIFR platform, officially launched its internal biobank. The biobank securely stored cryopreserved human gut microbiome samples along with detailed donor metadata. This development helped accelerate experimentation workflows by enabling rapid, targeted access to samples for client research.
• In March 2025, the NIPH Biobank became the first biobank in Norway to receive ISO 20387 accreditation. This certification confirmed its quality, traceability, and competence in handling biological samples. The achievement boosted public trust and supported research collaborations nationally and internationally.

Report Coverage:

By Type

• Equipment
  • Sample Collection Systems
  • Processing Equipment
  • Storage Equipment
  • Sample Transport Systems
• Consumables
  • Cryovials & Tubes
  • Reagents & Kits
  • Cryogenic Labels & Racks
  • Bags & Containers
• Services
  • Biobanking & Repository Services
  • Sample Processing & Analysis Services
  • Genomic Sequencing Services
  • Others

By Application

• Regenerative Medicine
• Life Science Research
• Clinical Research
• Drug Discovery & Development
• Personalized Medicine
• Disease Epidemiology
• Others

By Sample Type

• Blood Products
• Human Tissues
• Stem Cells
• DNA/RNA Samples
• Cells & Cell Lines
• Others

By Storage Type

• Manual Storage
• Automated Storage
• Cryogenic Storage
• Mechanical Storage

By End User

• Hospitals & Diagnostic Centers
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Thermo Fisher Scientific Inc.
• Tecan Group Ltd.
• Qiagen N.V.
• Hamilton Company
• Azenta Life Sciences
• TTP Labtech Ltd.
• Avantor, Inc.
• Promega Corporation
• Worthington Industries
• Chart Industries
• Becton, Dickinson and Company (BD)
• Merck KGaA
• Micronic
• LVL Technologies GmbH & Co. KG
• Panasonic Holdings Corporation

Frequently Asked Questions (FAQs)